<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390907</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008877</org_study_id>
    <nct_id>NCT03390907</nct_id>
  </id_info>
  <brief_title>Hybrid APC Assisted EMR for Large Colon Polyps</brief_title>
  <official_title>Hybrid APC Assisted EMR for Large Colon Polyps to Reduce Local Recurrence : A Prospective Data Collection Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to evaluate and examine whether use of Hybrid Argon Plasma&#xD;
      Coagulation (APC) as an adjunct to endoscopic mucosal resection (EMR) will reduce the risk of&#xD;
      residual or recurrent neoplasia at 6 months. Hybrid APC is an existing FDA approved device&#xD;
      used to assist with ablation of abnormal tissue anywhere in the GI tract.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colon Cancer is a major disease that effects more than 1 million people per year globally.&#xD;
      Adenomatous polyps have been identified as the main precursor leading to colorectal cancer.&#xD;
      Colon cancer screening is the best way to detect and remove large, often asymptomatic polyps.&#xD;
      Early detection and resection of these colorectal polyps can prevent the development of colon&#xD;
      cancer. Endoscopic mucosal resection (EMR) is a technique used for resection of medium to&#xD;
      large colon polyps. In this technique, fluid is injected into the submucosa creating a&#xD;
      cushion between the mucosa and the muscularis propria. An electrocautery snare is then&#xD;
      deployed to resect the polyp in a single (en-bloc) or multiple (piecemeal) pieces. Most&#xD;
      polyps &gt;2 cm are resected in piecemeal way. Although EMR is now considered standard of care&#xD;
      with a successful resection rate of 85 % and low risk of complication (3-10% bleeding and 1%&#xD;
      perforation), this technique has inherent deficiencies, especially piecemeal EMR. Recurrence&#xD;
      rates following piecemeal EMR can be as high as 20%. Resection of scarred polyps using this&#xD;
      technique is particularly challenging due to the non-lifting of the polyp. Endoscopic&#xD;
      submucosal dissection (ESD) is an alternative approach that aims to remove non- pedunculated&#xD;
      precancerous or cancerous lesions over 20 mm in one piece (en-bloc resection rate of 89.95%&#xD;
      and lesion recurrence rate of 0.7%). However, due to its technical complexity and high&#xD;
      complication risk (mainly bleeding and perforation, with complication rates approximately&#xD;
      8%), it is not the current standard of care and only performed by experts in the technique.&#xD;
&#xD;
      Hybrid Argon plasma coagulation (APC) is a new technique in which the endoscopist reinjects&#xD;
      the submucosa with fluid to create a cushion (normal saline/ diluted adrenaline and /or&#xD;
      sodium hyaluronate solution) to protect the muscle layer and then ablation is done using&#xD;
      spray argon coagulation to treat any microscopic residual disease that is the seed for local&#xD;
      recurrence. Previous studies have shown that this technique is a safe and easily applicable&#xD;
      technique to complete resection for recurrent polyps after first EMR.&#xD;
&#xD;
      Investigators hypothesize that with Hybrid APC assisted EMR there will be a decrease in&#xD;
      recurrence rate after 6 months and it will be more effective compared to the standard EMR&#xD;
      procedure.&#xD;
&#xD;
      This is a pilot study in which patients with non-pedunculated large polyps ≥ 20mm undergoing&#xD;
      endoscopic mucosal resection (EMR) will be recruited. Following standard EMR all patients&#xD;
      will undergo adjuvant Hybrid Argon Plasma Coagulation (APC) of the base and edges of the&#xD;
      polypectomy site to fulgurate any potential microscopic residual disease. Resected polyps&#xD;
      will be sent to the pathology laboratory where pathologist determine the final diagnosis of&#xD;
      the polyps as per standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Actual">October 27, 2020</completion_date>
  <primary_completion_date type="Actual">October 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a pilot study design in which patients with non-pedunculated large polyps ≥ 20mm undergoing EMR will be recruited. Following standard EMR all patients will undergo adjuvant Hybrid Argon Plasma Coagulation (APC) of the base edges of the polypectomy site to fulgurate any potential microscopic residual disease.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Following Standard EMR all patients will undergo adjuvant Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Having Complete Resection</measure>
    <time_frame>6 months post initial procedure</time_frame>
    <description>The primary outcome of interest will be the percentage of participants having complete resection at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Within 30 Days of Procedure Adverse Events ( Post-polypectomy Bleeding and Post-polypectomy Syndrome)</measure>
    <time_frame>30 days</time_frame>
    <description>The secondary outcome of interest will be measure of major adverse event rate, mainly post-polypectomy bleeding and post-polypectomy syndrome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Colon Polyp</condition>
  <condition>Colon Adenoma</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Hybrid APC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid APC</intervention_name>
    <description>Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.</description>
    <arm_group_label>Hybrid APC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient aged ≥18 and ≤89 of any gender, ethnicity and race referred to endoscopy&#xD;
             for resection of large colon polyps&#xD;
&#xD;
          -  Patients with a ≥20mm colon non-pedunculated polyp&#xD;
&#xD;
          -  Ability to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known (biopsy proven) invasive carcinoma in a potential study polyp&#xD;
&#xD;
          -  Pedunculated polyps (as defined by Paris Classification type Ip or Isp)&#xD;
&#xD;
          -  Patients with ulcerated depressed lesions (as defined by Paris Classification type&#xD;
             III)&#xD;
&#xD;
          -  Patients with inflammatory bowel disease&#xD;
&#xD;
          -  Patients who are receiving an emergency colonoscopy&#xD;
&#xD;
          -  Poor general health (ASA class&gt;3)&#xD;
&#xD;
          -  Patients with coagulopathy with an elevated INR ≥1.5, or platelets &lt;50&#xD;
&#xD;
          -  Poor bowel preparation&#xD;
&#xD;
          -  Target sign or perforation during initial EMR&#xD;
&#xD;
          -  Need for ESD for complete resection prior to APC&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Levenick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <results_first_submitted>October 6, 2021</results_first_submitted>
  <results_first_submitted_qc>November 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2021</results_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>John M. Levenick</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Colon polyp</keyword>
  <keyword>EMR</keyword>
  <keyword>Hybrid-APC</keyword>
  <keyword>Laterally spreading tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03390907/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients in Hershey Medical Center with a known ≥ 20mm polyp detected at a prior colonoscopy who were referred for colonoscopy procedure were identified as potential study participants.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hybrid APC</title>
          <description>Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.&#xD;
Hybrid APC: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participant population was 10% (n=4) African American and 90% (n=36) with 100% (n=40) non-Hispanic/Latino population</population>
      <group_list>
        <group group_id="B1">
          <title>Hybrid APC</title>
          <description>Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.&#xD;
Hybrid APC: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Measurement of polyps in mm</title>
          <description>Included polyps were a median size of 27 mm (IQR: 14.5 mm) and predominantly located in the ascending colon (31.8%), cecum (25.0%), and transverse colon (20.5%).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Having Complete Resection</title>
        <description>The primary outcome of interest will be the percentage of participants having complete resection at 6 months.</description>
        <time_frame>6 months post initial procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid APC</title>
            <description>Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.&#xD;
Hybrid APC: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.&#xD;
0% of recurrence in 32 cases who completed post-procedure colonoscopy 6 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Having Complete Resection</title>
          <description>The primary outcome of interest will be the percentage of participants having complete resection at 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure of Within 30 Days of Procedure Adverse Events ( Post-polypectomy Bleeding and Post-polypectomy Syndrome)</title>
        <description>The secondary outcome of interest will be measure of major adverse event rate, mainly post-polypectomy bleeding and post-polypectomy syndrome</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid APC</title>
            <description>Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.&#xD;
Hybrid APC: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Within 30 Days of Procedure Adverse Events ( Post-polypectomy Bleeding and Post-polypectomy Syndrome)</title>
          <description>The secondary outcome of interest will be measure of major adverse event rate, mainly post-polypectomy bleeding and post-polypectomy syndrome</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At 30 days following the initial resection, the research coordinator called each patient to assess for any signs of post-procedural adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hybrid APC</title>
          <description>Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.&#xD;
Hybrid APC: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Levenick</name_or_title>
      <organization>Penn State Milton S. Hershey Medical Center</organization>
      <phone>717-531-3834</phone>
      <email>jlevenick@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

